Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Malignant Melanoma

Interventions

DRUG

68Ga-PSMA

This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.

Trial Locations (1)

RECRUITING

The Royal Marsden NHS Foundation Trust, London

All Listed Sponsors

lead

Royal Marsden NHS Foundation Trust

OTHER